NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of LifeMD, Inc. (NASDAQ: LFMD)?Did you purchase your shares between May 7, 2025 and August 5, 2025, inclusive?Did you lose money in your inve ...

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). ...

Group 1 - A class action lawsuit has been filed against LifeMD, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors have until October 27, 2025, to request appointment as Lead Plaintiff if they purchased LifeMD securities during the Class Period [2] - Following the announcement of revised full-year 2025 guidance due to challenges in the Rex MD business, LifeMD's stock price dropped by $5.31, or 44.85%, closing at $6.53 per share [4] Group 2 - LifeMD's CFO stated that the company anticipates strong year-over-year growth in revenue and adjusted EBITDA despite temporary challenges [4] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding LifeMD's competitive position and failed to account for rising customer acquisition costs, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [3][4]. Group 1: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position [3]. - It is claimed that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - As a result, statements made by the defendants regarding LifeMD's business and prospects were materially false and misleading [3]. Group 2: Financial Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous guidance of $268 to $275 million [4]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [4]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against LifeMD is October 27, 2025 [1].

Core Viewpoint - LifeMD, Inc. is facing a class action lawsuit due to alleged securities fraud, with a significant stock price drop following the company's revision of its revenue and EBITDA guidance for 2025 [2][3]. Group 1: Company Performance - On August 5, 2025, LifeMD announced a revision of its full-year 2025 guidance for revenue and adjusted EBITDA due to temporary challenges in its Rex MD business [2]. - Following this announcement, LifeMD's stock price fell by $5.31, or 44.8%, closing at $6.53 per share on August 6, 2025 [2]. Group 2: Allegations in the Lawsuit - The class action complaint alleges that LifeMD's management made materially false and misleading statements regarding the company's business and operations during the class period [3]. - Specific allegations include that the management overstated LifeMD's competitive position and failed to account for rising customer acquisition costs in its RexMD segment [3]. - The lawsuit claims that positive statements made by the management lacked a reasonable basis and were materially misleading [3]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities during the class period are encouraged to file a lead plaintiff motion by October 27, 2025 [4]. - The law firm Glancy Prongay & Murray LLP is leading the class action and is available for inquiries regarding participation [5][6].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook during the specified class period [1][3]. Company Overview - LifeMD, Inc. is a telehealth provider based in New York, offering direct-to-patient virtual care and pharmacy services [2]. Allegations - The lawsuit claims that LifeMD overstated its competitive position and raised its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs like Wegovy and Zepbound [3]. - Following the revelation of the true facts, LifeMD's shares experienced a significant decline of 44%, equating to a drop of $5.31 per share in a single trading session [3]. Investor Information - Investors who acquired LifeMD securities during the class period have until October 27, 2025, to seek appointment as lead plaintiff representative of the class [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in LifeMD to contact them directly to discuss their legal options [1][9]. - A federal securities class action has been filed against LifeMD, with a deadline of October 27, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs [6]. - Specific issues cited include the failure to disclose rising customer acquisition costs in the RexMD segment and costs related to obesity treatment drugs [6]. Group 3: Financial Impact - On August 5, 2025, LifeMD revised its revenue guidance, expecting total revenue in the range of $250 to $255 million, down from a previous estimate of $268 to $275 million [7]. - Following this announcement, LifeMD's stock price dropped by 44.8% on August 6, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its competitive position and financial guidance [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD misled investors about its competitive position and raised its fiscal year 2025 performance guidance without proper justification [4]. - The company reportedly ignored critical factors such as customer acquisition costs for weight loss drugs, leading to materially misleading public statements throughout the class period [4]. - As a result of the misleading information, investors suffered damages when the truth about LifeMD was revealed [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025, and August 5, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint asserts that LifeMD's management materially overstated the company's competitive position [2]. - It is claimed that the company was reckless in raising its 2025 guidance without properly accounting for increasing customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - As a result, statements made by the defendants about LifeMD's business operations and prospects were materially false and misleading [2]. Financial Impact - On August 5, 2025, LifeMD revised its full-year 2025 guidance for revenue and adjusted EBITDA due to "temporary challenges" in its RexMD business, which led to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can remain absent class members if they choose not to participate [4]. Company Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5].